Amgen Inc. and Lundquist Institute for Biomedical Innovation announced Diadem Biotherapeutics as the recipient of the first Amgen Golden Ticket in Southern California.  

Diadem is researching “synthetic biosignaling” to treat with autoimmune diseases and cancer. 

As winner of the Golden Ticket, the company will have a year of lab space at BioLabs LA at Lundquist Institute in Torrance. Also, it will have access to additional facility benefits and connections to science and business leaders at Amgen in Thousand Oaks.   


Join our Membership to get the full story.

Are you a current Member? Sign In